Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) is set to issue its quarterly earnings data after the market closes on Monday, November 6th. Analysts expect the company to announce earnings of ($0.70) per share for the quarter.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings results on Thursday, August 10th. The biopharmaceutical company reported ($1.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.54). The firm had revenue of $0.25 million for the quarter, compared to analysts’ expectations of $0.08 million. Dicerna Pharmaceuticals had a negative return on equity of 168.65% and a negative net margin of 8,474.12%. Dicerna Pharmaceuticals’s revenue was up 2400.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.75) EPS. On average, analysts expect Dicerna Pharmaceuticals to post $-3.13 EPS for the current fiscal year and $-3.19 EPS for the next fiscal year.

Shares of Dicerna Pharmaceuticals, Inc. (NASDAQ DRNA) opened at 5.15 on Monday. The stock’s 50 day moving average price is $5.07 and its 200 day moving average price is $3.73. Dicerna Pharmaceuticals, Inc. has a 52 week low of $2.42 and a 52 week high of $6.75. The stock’s market cap is $107.35 million.

ILLEGAL ACTIVITY NOTICE: “Dicerna Pharmaceuticals, Inc. (DRNA) Scheduled to Post Quarterly Earnings on Monday” was first reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/30/dicerna-pharmaceuticals-inc-drna-scheduled-to-post-quarterly-earnings-on-monday.html.

A number of research analysts recently commented on DRNA shares. Chardan Capital reiterated a “hold” rating on shares of Dicerna Pharmaceuticals in a research note on Monday, August 14th. Zacks Investment Research upgraded shares of Dicerna Pharmaceuticals from a “strong sell” rating to a “buy” rating and set a $6.25 price objective on the stock in a research note on Monday, October 23rd. Finally, ValuEngine upgraded shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, July 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. Dicerna Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $5.56.

A hedge fund recently raised its stake in Dicerna Pharmaceuticals stock. Northern Trust Corp raised its holdings in shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) by 6.1% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 36,219 shares of the biopharmaceutical company’s stock after buying an additional 2,094 shares during the period. Northern Trust Corp owned about 0.17% of Dicerna Pharmaceuticals worth $114,000 as of its most recent SEC filing. 55.94% of the stock is currently owned by institutional investors.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Earnings History for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.